Sign in
Taking peoplePhase 3

Biomarker-Guided Early Clarithromycin Treatment To Prevent Sepsis Progression In Community-Acquired Pneumonia: The REACT Randomized Clinical Trial

Key facts

Who runs it
Hellenic Institute For The Study Of Sepsis
Where
Greece20 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
330 people, planned
Started
12 Feb 2024
Planned end
30 Jul 2026
Type of study
Interventional
Record updated
28 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Age equal to or above 18 years
  • Male or female gender
  • In case of women of reproductive age, willingness to use dual contraceptive method during the study period
  • Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation
  • Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain
  • Community-acquired pneumonia (CAP)
  • PCT ≥0.25 ng/ml
  • suPAR ≥6 ng/ml

Who cannot take part

  • Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation
  • Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation
  • Concomitant presence of end-stage liver failure and end-stage renal failure
  • Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days
  • Known infection by the human immunodeficiency virus
  • Medical history of allergy to macrolides
  • Medical history of torsades de pointes arrhythmia
  • Any stage IV malignancy
  • Infection by SARS-CoV-2
  • QTc interval at rest in the ECG ≥500 msec or history of know long QT syndrome
  • Age below 18 years
  • Any chronic anti-cytokine treatment for more than two months
  • Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored
  • Any contradictions for macrolide uptake
  • Denial of written informed consent
  • Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
  • Participation in any other interventional trial
  • Any do not resuscitate decision
  • Patients necessitating non-invasive ventilation or mechanical ventilation
  • Hospitalization in Intensive Care Unit
  • Intake of any macrolide for the current episode of CAP under study

This trial is currently available in Greece.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with CAP at risk.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
28 July 2026